RedHill Biopharma Ltd. (RDHL)
2.26
-0.15 (-6.22%)
At close: Apr 14, 2025, 3:59 PM
2.21
-2.21%
After-hours: Apr 14, 2025, 07:59 PM EDT
-6.22% (1D)
| Bid | 2.12 |
| Market Cap | 9.9K |
| Revenue (ttm) | 35.74M |
| Net Income (ttm) | -10.8M |
| EPS (ttm) | -302.63 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | 211 |
| Analyst | n/a |
| Ask | 2.31 |
| Volume | 18,026 |
| Avg. Volume (20D) | 95,237 |
| Open | 2.49 |
| Previous Close | 2.41 |
| Day's Range | 2.20 - 2.44 |
| 52-Week Range | 1.80 - 20.27 |
| Beta | 4.43 |
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development pr...
Sector Healthcare
IPO Date Jan 7, 2013
Employees 53
Stock Exchange NASDAQ
Ticker Symbol RDHL
Website https://www.redhillbio.com
7 months ago
+25.06%
Redhill Biopharma shares are trading higher after ...
Unlock content with
Pro Subscription
7 months ago
+10.76%
Redhill Biopharma shares are trading higher after the company announced results from multiple in vivo studies.
